D. Meili

发表

Heroin substitution: an exception or an expanded feasibility for providing hepatitis treatment to drug users?

P. Bruggmann, A. Kormann, D. Meili, 2009 .

Hepatitis C Treatment in Patients receiving Opiate Substitution Recommendations of the Swiss Association for Addiction Medicine (SSAM)

P. Bruggmann, B. Broers, D. Meili, 2007 .

Barrier Capacity of Human Placenta for Nanosized Materials

Peter Wick, Harald F. Krug, H. Krug, 2009, Environmental health perspectives.

Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations

M. Preisig, C. Eap, G. Bertschy, 2001, Journal of clinical psychopharmacology.

A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland

B. Somaini, M. Flepp, P. Grob, 2000, AIDS care.

Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment.

J. Hättenschwiler, J. Modestin, Edi Böni, 2005, Journal of substance abuse treatment.

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients

F. Negro, O. Keiser, P. Bruggmann, 2008, Journal of viral hepatitis.

581 Hepatitis C virus treatment in injecting drug users: Frequency of contraindications and prognostic markers in participants of the Swiss hepatitis C cohort study

P. Bruggmann, M. Isler, D. Meili, 2006 .

Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial

R. Weber, P. Vernazza, P. Schmid, 2005, Infection.

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients

O. Keiser, P. Bruggmann, L. Falcato, 2008, Journal of viral hepatitis.